Prostamax is a bioregulatory peptide primarily studied in prostate and urogenital system research. It has been widely used in studies related to cellular regulation, tissue differentiation, and age-related functional changes within prostate tissues.
私たちのProstamax 20mgis manufactured under strict quality control standards to ensurehigh purity, structural stability, and consistent batch performance. The lyophilized presentation allows for easy handling, extended shelf life, and reliable storage conditions.
This peptide is suitable for research facilities, pharmaceutical development teams, and peptide distributors specializing in urogenital and endocrine-related research.
Chronic prostate inflammation (called chronic prostatitis) affects as many as 16% of men at some point in their lives. It is a painful condition causing burning with urination, urgency, and trouble voiding. It can even cause difficult or painful ejaculation along with pain in the lower back. It is notoriously difficult to treat, often requiring long-term antibiotic treatment over months. There is also good evidence to suggest that it can lead to cardiovascular disease and even cancer, so treating prostatitis is crucial to long-term health[2].
Research in rat models shows that prostatitis can be treated with Prostamax, which reduces the signs and symptoms of the disease. Rats treated with Prostamax for just 15 days showed reduce swelling of the prostate gland along with less vascular congestion (hyperemia) and less infiltration by cells of the immune system. Interestingly, the rats also showed decreased levels of scarring in the prostate, indicating that the reduction in inflammation was slowing or even stopping pathological remodeling. Though the study was not carried out long enough or on enough rats to assess Prostamax’s effect on the risk for cancer, the results suggest that it would likely diminish the risk by reducing chronic inflammation that leads to pathological hypertrophy and hyperplasia[3].
According to Dr. Angelina Pakhomova, what makes the above study on Prostamax extra exciting is that it was effective in treating a form of prostatitis called chronic abacterial prostatitis (CAP). CAP is the most common form of prostatitis, but it is difficult to treat because it isn’t caused by a bacterial infection. Bacterial infections respond readily to antibiotics. CAP, on the other hand, does not respond as well to antibiotic treatment and sometimes doesn’t respond at all. It is also more likely to recur and has been shown to be exceptionally frustrating to those who suffer from it. Having an alternative treatment that is effective in CAP could improve quality of life for many men and ward off future disease. Finding a treatment for CAP is more important than ever as rates of the condition have increased almost 3-fold since the end of the 20th世紀。
プロスタマックスと免疫系
Though Prostamax is considered to be tissue-specific, there is ample evidence that the bioreulator acts on cells outside of the prostate. The most consequential effects are on the ribosomes and densely packed chromatin found in lymphocytes. In these cells, Prostamax, like Epithalon and Vilon, serves to increase expression of ribosomes which are responsible for the translation of mRNA into proteins. It also opens up densely packed chromatin to make genes more accessible for transcription into mRNA. Thus, Prostamax sets the stage for increased gene expression at every level, allowing for a functional change in the health of lymphocytes[4], [5].
The impact of Prostamax on the immune system is not just theoretical either. Research shows that the peptide helps to reduce signs of chronic prostate inflammation including swelling, hyperemia, and lymphocyte infiltration.[3] This results both from the influence Prostamax has on lymphocytes and their control over the immune response as well as the role the peptide plays in normalizing growth and differentiation of prostate cells.
プロスタマックスと老化
The effects that Prostamax has on lymphocytes and cells of the prostate are part of a larger effect it has one many different types of cells. Research in cell cultures taken from older individuals shows that Prostamax alters DNA structure by decondensing heterochromatin. This, in turn, allows for greater expression of DNA that was inactivated via dense packaging of DNA[6].
What makes this remarkable in terms of aging is that condensation of DNA is a normal, if undesirable, consequence of aging. DNA condensation is a primary driver of both senescence and apoptosis, making it one of the most important mechanisms of aging. By unpacking DNA, Prostamax is literally giving the cells a more youthful genetic profile. The results are increased proliferation of cells, decreased apoptosis (programmed cell death), and improved protein expression and cell function.
Interestingly, Prostamax and similar epigenetically active peptides are found naturally in long-lived rodent species like the African mole rat. These same peptides areない短命種[7]で見つかりました。これは、プロスタマックスのようなペプチドで観察されたエピジェネティックな効果は、実際には老化と寿命に直接関連していることを示しています。
ウラジミール・ハビンソン老年学と老年学の国際協会の欧州地域の教授であり、ヨーロッパ地域の会長です。のメンバー医学科学のロシア語とウクライナのアカデミー;ロシア州政府政府の保健委員会の主要老年学者。聖ペテルブルク生物調節および老年学研究所のディレクター。老年学会の副会長ロシア科学アカデミー;セントペテルブルクの老年医学および老年科学老年科学部長。医療サービス大佐（ロシア、ソ連）、退職。VladimirKhavinsonは、新しいクラスの発見、実験、臨床研究で知られていますペプチド生体調節因子と生体育成ペプチド療法の開発。彼は、老化のメカニズムの調節におけるペプチドの役割を研究することに従事しています。彼の主な行動分野は、新しいペプチドの設計、臨床前、臨床研究ですゼロゲロテクター. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications.His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002)and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005).Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.
Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Prostamax. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
A. N. Zakutskiĭ, N. I. Chalisova, G. A. Ryzhak, A. I. Aniskina, S. V. Filippov, and P. N. Zeziulin, “[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats],”Adv. Gerontol. Uspekhi Gerontol., vol. 19, pp. 93–96, 2006.
“Treating chronic prostatitis,”Harvard Health, Dec. 21, 2017. https://www.health.harvard.edu/mens-health/treating-chronic-prostatitis (accessed Feb. 22, 2022).
T. G. Borovskayaet al., “Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications,”Mod. Res. Inflamm., vol. 2013, Jul. 2013, doi: 10.4236/mri.2013.23007.
V. K. Khavinson, T. A. Lezhava, and V. V. Malinin, “Effects of short peptides on lymphocyte chromatin in senile subjects,”Bull. Exp. Biol. Med., vol. 137, no. 1, pp. 78–81, Jan. 2004, doi: 10.1023/b:bebm.0000024393.40560.05.
T. Meskhiet al., “[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ],”Biofizika, vol. 49, no. 6, pp. 1091–1093, Dec. 2004.
T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaĭozishvili, N. A. Baratashvili, and T. A. Lezhava, “[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)],”Georgian Med. News, no. 212, pp. 76–82, Nov. 2012.
V. K. Khavinson, D. Y. Kormilets, and A. T. Mar’yanovich, “Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan,”Bull. Exp. Biol. Med., vol. 163, no. 5, pp. 671–676, Sep. 2017, doi: 10.1007/s10517-017-3876-x.このウェブサイトで提供されるすべての記事と製品情報は、情報および教育目的のみを目的としています。このウェブサイトで提供される製品は、ビトロ内の研究のためにのみ提供されています。 in-vitro研究（ラテン語：ガラス）は体の外側で行われます。これらの製品は薬や薬ではなく、病状、病気、病気を予防、治療、治療するためにFDAによって承認されていません。あらゆる種類の人間や動物への身体導入は、法律によって厳密に禁じられています。
